ROLE OF INTERLEUKIN--6 AND PROCALCITONIN AS INFLAMMATORY BIOMARKERS IN EVALUATING COVID--19 DISEASE SEVERITY ON HRCT CHEST-- AN EXPERIENCE AT CMH QUETTA
Pakistan Armed Forces Medical Journal
; 71(6):2131-2134, 2021.
Article
in English
| Scopus | ID: covidwho-1841855
ABSTRACT
Objective:
To explore the relation of Interleukin-6 and Procalcitonin with COVID-19 severity on high resolution computerized tomogram (HRCT) chest. StudyDesign:
Randomized Control Trial (NCT04945811). Place and Duration of study Pathology Department, Combined Military Hospital Quetta, from April 2020 to May 2021.Methodology:
Serum Interleukin-6 and Procalcitonin of 100 consenting COVID-19 positive patients from April 2020 to May 2021 were assessed at Pathology department Combined Military Hospital Quetta and their levels were correlated with severity of lung involvement on HRCT ChestResults:
Serum Interlukin-6 levels were significantly raised in 97 patients with mean levels of 20.43 ± 19.66 (pg/ml). Serum procalcitonin levels were also significantly raised in 95 patients with mean levels of 0.43 ± 0.24 (ng/ml).Conclusion:
Interlukin-6 and procalcitonin are important biomarkers for diagnosis and predicting severity of COVID-19 pneumonia. © 2021, Army Medical College. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Pakistan Armed Forces Medical Journal
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS